<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691246</url>
  </required_header>
  <id_info>
    <org_study_id>GUSU17003</org_study_id>
    <nct_id>NCT03691246</nct_id>
  </id_info>
  <brief_title>Research on Burden of Disease for Patients With Myocardial Infarction Combining Dyslipidemia in China</brief_title>
  <official_title>Research on Burden of Disease for Patients With Myocardial Infarction Combining Dyslipidemia in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Cardiovascular Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Cardiovascular Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is medical record review and questionnaire survey on the economic burden on
      Chinese patients with myocardial infarction accompanied by dyslipidemia in a real-world
      environment.

      The primary objective of the study is to investigate the economic burden of disease on
      patients and the factors influencing it, which may include the mode of treatment for
      dyslipidemia, drugs for the secondary prevention of myocardial infarction, the outcome of
      treatment for dyslipidemia, adverse drug reactions and major cardiovascular events.

      The secondary objectives of the study include:

        1. patient compliance with medication;

        2. health-related quality of life (HRQoL) in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter retrospective cohort survey study using a cross-sectional design.
      It is conducted mainly by a medical record review, questionnaire survey and medical
      examination to collect data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Economic burden of disease</measure>
    <time_frame>2 to 3 years</time_frame>
    <description>Total of costs for outpatient/emergency visits after discharge since &quot;index hospitalization&quot; (e.g., registration fees, examination fees, inspection fees, charges for drugs and other expenses), inpatient expenses (e.g., charges for percutaneous coronary intervention /coronary artery bypass graft, bed fees, charges for drugs, charges for materials, charges for nursing care and other expenses), payments for health care workers, fees for transportation, fees for accommodation and food, costs due to losses of time and capacity for physical labor for patients and their families, charges for visits to other medical institutions due to dyslipidemia and related diseases, as well as expenses for medications and health products purchased from drug stores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>2 to 3 years</time_frame>
    <description>The EuroQol five dimensions questionnaire with three-level (EQ-5D-3L) scores are calculated using the scoring system for the Chinese population. Then, the mean and standard deviation of health utility values (HUVs) are reported.
EQ-5D-3L is a standardized instrument for use as a measure of health outcome. The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1 point), some problems (2 points), extreme problems (3 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient compliance with medication</measure>
    <time_frame>2 to 3 years</time_frame>
    <description>Medication compliance is reported mainly based on the frequency of oral administration on time and the percentage of patients taking drugs on time, which are assessed by patients themselves in the questionnaire.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Dyslipidemias</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients were hospitalized because of acute myocardial infarction in a study hospital
        between January 1, 2016 and December 31, 2016. If a patient was hospitalized because of
        multiple occurrences of myocardial infarction during this period, his/her initial
        hospitalization because of myocardial infarction will be considered index hospitalization.
        Patients undergo continuous screening in a reverse order based on time.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients were hospitalized because of acute myocardial infarction in a study hospital
             between January 1, 2016 and December 31, 2016. If a patient was hospitalized because
             of multiple occurrences of myocardial infarction during this period, his/her initial
             hospitalization because of myocardial infarction will be considered index
             hospitalization. Patients undergo continuous screening in a reverse order based on
             time.

          -  Patients did not die during &quot;index hospitalization&quot;.

          -  Patients had Low-density lipoproteinâ‰¥1.8 mmol/L shown by the first measurement of
             blood lipids or were using lipid-regulating drugs at the first measurement of blood
             lipids during &quot;index hospitalization&quot; in 2016.

          -  Patients consent to participate in this study and grant informed consent; or the
             family of a patient who died before telephone screening consents to provide relevant
             information and grant informed consent.

        Exclusion Criteria:

          -  Patients participated in interventional clinical trials after &quot;index hospitalization&quot;.

          -  Patients had paid &lt;5 visits to the outpatient clinics of a study hospital within one
             year since discharge after &quot;index hospitalization&quot; (if patients who have died within
             one year since discharge after &quot;index hospitalization&quot;).

          -  There is a barrier to communication with a patient or his/her family (if the patient
             has died); a patient or his/her family (if the patient has died) cannot correctly
             understand and answer questions normally.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Huo, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Huo, master</last_name>
    <phone>13901333060</phone>
    <email>drhuoyong@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zhang, doctor</last_name>
    <phone>13621062738</phone>
    <email>drzhy1108@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Jiyan, MD</last_name>
      <phone>020-83827812</phone>
      <email>chen-jiyan@163.com</email>
    </contact>
    <contact_backup>
      <last_name>He Peiyu</last_name>
      <email>emily_hpy@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chen Jiyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Xi, MD</last_name>
      <email>yaxin_suxi@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shuang Dongsi</last_name>
      <email>sds97@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Su Xi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuang Dongsi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Biao, MD</last_name>
      <email>xubiao62@nju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Li Peiwen, MD</last_name>
      <email>13805174693@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xu Biao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Peiwen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ge Junbo, MD</last_name>
      <email>ge.junbo@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wang Zhen, MD</last_name>
      <email>wang.zhen1@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ge Junbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wang Zhen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Jianhong, MD</last_name>
      <email>taojianhong06@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Huang Hao</last_name>
      <email>34266129@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Jianhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huang Hao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.</citation>
    <PMID>16214597</PMID>
  </reference>
  <reference>
    <citation>Bays HE, Chapman RH, Fox KM, Grandy S; SHIELD Study Group. Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia. Curr Med Res Opin. 2008 Apr;24(4):1179-86. doi: 10.1185/030079908X280527 . Epub 2008 Mar 14.</citation>
    <PMID>18346311</PMID>
  </reference>
  <reference>
    <citation>Joffres M, Shields M, Tremblay MS, Connor Gorber S. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. Can J Public Health. 2013 Apr 24;104(3):e252-7.</citation>
    <PMID>23823891</PMID>
  </reference>
  <reference>
    <citation>Alhabib KF, Sulaiman K, Al-Motarreb A, Almahmeed W, Asaad N, Amin H, Hersi A, Al-Saif S, AlNemer K, Al-Lawati J, Al-Sagheer NQ, AlBustani N, Al Suwaidi J; Gulf RACE-2 investigators. Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2). Ann Saudi Med. 2012 Jan-Feb;32(1):9-18.</citation>
    <PMID>22156634</PMID>
  </reference>
  <reference>
    <citation>Tuppin P, RiviÃ¨re S, Rigault A, Tala S, Drouin J, Pestel L, Denis P, Gastaldi-MÃ©nager C, Gissot C, JuilliÃ¨re Y, Fagot-Campagna A. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Arch Cardiovasc Dis. 2016 Jun-Jul;109(6-7):399-411. doi: 10.1016/j.acvd.2016.01.011. Epub 2016 Apr 11.</citation>
    <PMID>27079468</PMID>
  </reference>
  <reference>
    <citation>Mota D, Mattos AC, Oliveira G, Avezum A. The Need for Brazil to Focus on CVD. Glob Heart. 2016 Dec;11(4):439-440. doi: 10.1016/j.gheart.2016.10.001.</citation>
    <PMID>27938835</PMID>
  </reference>
  <reference>
    <citation>Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, Liu J, Cheng J, Bibbins-Domingo K, Shen YM, He J, Goldman L. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):243-52. doi: 10.1161/CIRCOUTCOMES.109.910711. Epub 2010 May 4.</citation>
    <PMID>20442213</PMID>
  </reference>
  <reference>
    <citation>Authors/Task Force Members:, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Å½, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.</citation>
    <PMID>27594540</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

